Global transient ischemic attack market is expected to reach USD 2467.82 Million by 2025, at a CAGR of 6.16% from 2018 to 2025. The rising prevalence of neurological disorders, increasing investments on biotechnology and pharmaceutical research activities, and the rising need for enhanced treatment methods are the factors that are driving the growth of the market.

Market Overview:

Transient ischemic attack (TIA) is also known as a “mini-stroke.” It is caused by a temporary disruption in the blood supply to part of the brain. The disruption in blood supply results in a lack of oxygen to the brain. This can cause sudden symptoms similar to a stroke, such as speech and visual disturbance, and numbness or weakness in the face, arms, and legs. About 1 in 3 people who have a transient ischemic attack will eventually have a stroke, with about half occurring within a year after the transient ischemic attack. According to the American Heart Association and American Stroke Association guidelines, patients that experience Transient Ischemic Attack (TIA) should undergo head imaging within 24 hours of symptom onset, preferably with magnetic resonance imaging, including diffusion sequences. MRI is a better imaging modality for the diagnosis of TIA than Computed Tomography (CT).


Report Description:

  • The base year for the study has been considered 2017, the historic year 2015 and 2016 and, the forecast period considered is from 2018 to 2025. The global transient ischemic attack market is analyzed by value (USD Million)
  • The study delivers a comprehensive analysis of global transient ischemic attack market by diagnosis, treatment end user and regions. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2018 to 2025.
  • Porter’s Five Forces model is used to recognize the competitive scenario in the global transient ischemic attack market. This report incorporates the industry analysis which is focused on providing an extensive view of the transient ischemic attack market.
  • The study also includes attractiveness analysis of diagnosis, treatment end, user and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
  • The report provides company profile of the key players operating in the transient ischemic attack market and a comparative analysis based on their business overviews, product offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
  • The market estimates have been evaluated by considering the effect of different political, economic, social, technological and legal factors which are based on our extensive secondary research, primary research, and in-house databases.

Market Dynamics:


  • The rising prevalence of neurological disorders
  • Growing geriatric population


  • The paucity of skilled physicians and surgeons


  • The growing preference for the wire-assisted surgery
  • Advancements in catheter devices technology


  • Rising treatment and hospitalization cost


Regional Segmentation Analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa.North America region emerged as a dominating region in global transient ischemic attack market with USD 587.29 million revenue in 2017. This increased market share can be attributed to rising prevalence of neurological disorders, high per capita healthcare expenditure, and increasing government support for research and development activities as well as presence of global pharmaceutical companies in the region.

Competitive Analysis:

Major players in the global transient ischemic attack market are Koninklijke Philips N.V., Stryker Corporation, Johnson & Johnson Services Inc., Boston Scientific Corporation, Sanofi SA, Bayer AG, Pfizer Inc., Siemens AG, F. Hoffmann-La Roche AG, GE Healthcare, Penumbra, Inc., Medtronic PLC, Abbott Laboratories, Merck & Co., Inc., and BoehringerIngelheim GmbH, LivaNova PLC, Cyberonics, Inc, NeuroMetrix, Inc. among others.

Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (, who will ensure that you get a report that suits your needs.